Human papillomaviruses: Into the new millennium

Obstetrics and Gynecology Clinics of North America

Volumn 28, Issue 4, 2001, Pages 653-666

  Unger, Elizabeth R ^a,b   Duarte Franco, Eliane ^b  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

VACCINE;

ASSAY; CANCER SCREENING; CONTACT EXAMINATION; DIAGNOSTIC PROCEDURE; DISEASE ASSOCIATION; HUMAN; IN SITU HYBRIDIZATION; INFECTION PREVENTION; NONHUMAN; PAPANICOLAOU TEST; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; TREATMENT INDICATION; UTERINE CERVIX CANCER; VACCINATION; VIRUS CARCINOGENESIS; VIRUS INFECTION; VIRUS TRANSMISSION; WART VIRUS;

EID: 0035202867     PISSN: 08898545     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8545(05)70227-8     Document Type: Article

References (47)

1. Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: Baseline data from a randomized trial
2. 1998 Guidelines for treatment of sexually transmitted diseases
3. Determinants of genital human papillomavirus infection in low-risk women in Portland, Oregon
4. A comprehensive program for cervical cancer detection and management
5. Prevalence of human papillomavirus in cervical cancer: A worldwide perspective
6. Sexual behavior and partner characteristics are the predominant risk factors for genital human papillomavirus infection in young women
7. Estimates of the incidence and prevalence of sexually transmitted diseases in the United States
8. Epidemiology of cervical intraepithelial neoplasia: The role of human papillomavirus
9. Human papillomavirus testing for primary cervical cancer screening
10. A systematic review of the role of human papillomavirus (HPV) testing within a cervical screening programme: Summary and conclusions
11. Cancer causes revisited: Human papillomavirus and cervical neoplasia
12. Assessing gains in diagnostic utility when human papillomavirus testing is used as an adjunct to Papanicolaou smear in the triage of women with cervical cytologic abnormalities
13. Screening for cervical cancer in Latin America: A case-control study
14. Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica
15. Natural history of cervicovaginal papillomavirus infection in young women
16. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia
17. Human papillomaviruses
18. Detection of high-risk cervical intraepithelial neoplasia and cervical cancer by amplification of transcripts derived from integrated papillomavirus oncogenes
19. Epidemiology of genital human papillomavirus infection
20. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection
21. "Pap" smear and the risk of cervical neoplasia: Quantitative estimates from a case-control study
22. Trends in mortality from cervical cancer in the Nordic countries: Association with organised screening programmes
23. Identifying women with cervical neoplasia: Using human papillomavirus DNA testing for equivocal Papanicolaou results
24. Natural history of cervical squamous intraepithelial lesions: A meta-analysis
25. Prevention of sexually transmitted infections through health education and counseling: A general framework
26. Report of a national workshop on screening for cancer of the cervix
27. Report on a workshop of the UICC project on evaluation of screening for cancer
28. Report on consensus conference on cervical cancer screening and management
29. The causal link between human papillomavirus and invasive cervical cancer: A population-based case-control study in Colombia and Spain
30. Human papillomavirus vaccines for cervical cancer
31. Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: A prospective study
32. Natural history of cervical intraepithelial neoplasia: A critical review
33. Human papillomavirus testing for primary screening of cervical cancer precursors
34. Human papillomavirus infection and cervical cancer in Latin America
35. Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia
36. HPV DNA testing in cervical cancer screening: Results from women in a high-risk province of Costa Rica
37. The epidemiology of cervical carcinogenesis
38. Papillomavirus-like particle vaccines for cervical cancer
39. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: Baseline results from a randomized trial
40. Concurrent and sequential acquisition of different genital human papillomavirus types
41. The association of human papillomavirus type 16 integration in the E2 gene with poor disease-free survival from cervical cancer
42. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide
43. Do HPV-negative cervical carcinomas exist?
44. Attempts to detect virus-specific DNA sequences in human tumors: Nucleic acid hybridization with complementary RNA of human wart virus